Selank

Selank is a lab-made peptide (a short chain of amino acids, the building blocks of proteins) that was developed in Russia and is sold online as an anti-anxiety and “nootropic” (brain-boosting) compound. There is real human research behind it, but it’s thin, almost all from Russia, and done on small numbers of people.

What it is

Selank is a synthetic heptapeptide, meaning a man-made chain of seven amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro). It’s based on tuftsin, a small natural fragment of an antibody (immunoglobulin G) that helps signal the immune system. Researchers at Russia’s Institute of Molecular Genetics tacked an extra piece onto tuftsin so it would last longer in the body before breaking down (extend its half-life). It’s usually given as a nasal spray, and in Russia it’s sold that way with a prescription.

The claims

Sellers and clinics pitch Selank for a long list of things: everyday anxiety, stress, a “benzodiazepine-level” sense of calm without the drowsiness or addiction, sharper focus, better mood, and a tuned-up immune system. (Benzodiazepines are common anti-anxiety drugs like Valium.) Some sites go further and claim it fights depression and protects the brain.

What the evidence actually shows

There is human data here, which is already more than you can say for a lot of peptides sold online. But the studies are small, usually open-label (meaning everyone knew who got the drug) or “add-on” (Selank given alongside another medication), short, and run by just a handful of Russian research groups. One comparison in 62 people with generalized anxiety disorder and neurasthenia (a dated term for chronic mental and physical fatigue) found Selank eased anxiety about as well as the benzodiazepine medazepam, and also helped with fatigue. A 2015 trial in 70 people found that adding Selank to the benzodiazepine phenazepam cut down on side effects while keeping the benefit. A 2008 study reported changes in immune markers called cytokines in patients with anxiety-and-exhaustion disorders.

These are genuine signals in real people. But none of them are large, none used a proper placebo group, none have been repeated by independent Western teams, and the full reports are often only available in Russian. Most of the other published work is in rats and mice (looking at morphine withdrawal, alcohol-related memory loss, and stress) or in cells grown in a dish. Worth noting: a 2017 lab study in cells, often cited as proof of how Selank works, actually found that it had no direct effect on the activity of GABA-related genes (GABA is a calming brain chemical). So how it actually works is still unclear. The popular “as good as a benzodiazepine, with none of the downsides” pitch goes well beyond what this evidence can back up.

Legal and regulatory status

Selank was approved by Russia’s Ministry of Health around 2009 and is available there by prescription as a 0.15% nasal spray for generalized anxiety disorder. It is not approved by the US FDA or by European regulators, and it isn’t an approved drug in most Western countries. It’s not a dietary supplement either. In the US it’s sold only as a “research chemical” labeled not for human consumption, which means there are no rules guaranteeing that what’s in the bottle is really Selank, that it’s pure, or that the dose is right.

One wrinkle on the US side: in 2026, HHS and the FDA hinted they might loosen the rules on compounding (custom-mixing by pharmacies) for a group of peptides, and Selank was reportedly on the list being considered. As of this writing that process isn’t finished; it’s still under FDA advisory-committee review. Even if it goes through, the most it would do is let compounding pharmacies make the peptide with a prescription. It would not mean FDA approval, which requires finished clinical trials for a specific use.

For athletes: Selank is not listed on the World Anti-Doping Agency (WADA) Prohibited List. WADA’s S0 category covers substances that no government health authority anywhere has approved for human medical use. Because Selank does have a Russian approval, whether it falls under S0 is genuinely murky rather than clear-cut. That uncertainty is itself a reason to be careful: any athlete who gets tested should check the status with their sport’s anti-doping authority before using it.

Safety

Short Russian trials describe Selank as easy to tolerate, with few reported side effects and no clear sign of the addiction or withdrawal you can get with benzodiazepines. But that reassurance comes from small, short studies. There’s no long-term safety data, no large safety database, and no solid information on how it interacts with other drugs or whether it’s safe in pregnancy. And anything sold as a “research chemical” carries an extra, unknown risk of being contaminated or mislabeled.

Bottom line

Selank is one of the better-studied “nootropic” peptides, with approval and real clinical use in Russia and actual human trials behind it. But by Western standards the evidence is still early-stage: small, short, from a single country, and mostly without proper control groups, with no FDA approval and no long-term safety data. Promising is not the same as proven. None of this is medical advice.

Evidence grade: 6/10 · Preliminary.

Sources

• Optimization of the treatment of anxiety disorders with selank (RCT, n=70). Zh Nevrol Psikhiatr Im S S Korsakova, 2015
• Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova, 2008
• Zozulya AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (selank vs medazepam, n=62), 2008
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol, 2017
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol, 2017
• WADA Prohibited List (category S0, non-approved substances)
• FDA moves toward easing restrictions on certain peptides. BioPharma Dive, 2026